Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526017 · ClinicalTrials.gov registry record · Phase 1
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 313
- Enrollment target
- 20
- Study locations
NCT02526017: Completed Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Five Prime Therapeutics.
NCT02526017 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that has completed, run by Five Prime Therapeutics. The registered enrollment target is 313 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02526017, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 313 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
Primary Outcome
A DLT was defined as a study drug-related ≥ Grade 3 AE (using National Cancer Institute Common Terminology Criteria for Adverse Events v 4.03) occurring during the first 28-days, excluding Grade 3 tumor flare (defined as local pain, irritation, or rash localized at sites of known or suspected tumor), rash, immune-related adverse event (irAE) that resolved to ≤ Grade 1 by 14 days or a transient (resolving within 6 hours of onset) Grade 3 infusion-related AE. Any recurrence of Grade 3 rash, irAE o
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Cabiralizumab
Study Locations (20)
California
- Moores UC San Diego Cancer Center - La Jolla
- Norris Comprehensive Cancer Center, University of Southern California - Los Angeles
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center - Los Angeles
- UC Davis Comprehensive Cancer Center - Sacramento
- University of California, San Francisco - San Francisco
- Sarcoma Oncology Research Center - Santa Monica
- UCLA Hematology/Oncology- Santa Monica - Santa Monica
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- Rush University Medical Center - Chicago
- University of Chicago Medical Center - Chicago
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Hospital - Detroit
Arizona
- Scottsdale Healthcare Hospitals DBA Honor Health - Scottsdale
Georgia
- Emory University Hospital - Atlanta
Indiana
- Indiana University Health Hospital - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2015-09-08 |
| Est. Completion | 2019-11-18 |
| Phase | Phase 1 |
What the finished NCT02526017 record still lists
NCT02526017 is an interventional study that assigns participants to a tested intervention. The registered 313 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% lower).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02526017 names 20 study sites across 11 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02526017 about?
NCT02526017 is a clinical study titled "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers". Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
What is the current status of trial NCT02526017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 313 participants. The study started on 2015-09-08. Estimated completion is 2019-11-18.
What conditions does trial NCT02526017 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, Advanced Solid Tumors.
What interventions are being tested in trial NCT02526017?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Cabiralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02526017?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02526017 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02526017's enrollment target sits among peer trials
313 121st of 454 higher than 333 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00595491 · 313 participants · Phase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI